#Japan #Tokyo #Metallo-Balance #Renatech #Sugamo Clinic

New Cancer and Cognitive Risk Assessment in Tokyo

In an exciting development for health monitoring, Renatech Co., based in Kanagawa Prefecture, has launched its innovative Metallo-Balance Test, which assesses the risks of cancer and Mild Cognitive Impairment (MCI) using just a minimal blood sample of 6mL. This revolutionary screening test will be available for booking at the Sugamo Clinic located in Toshima, Tokyo, starting this October.

The Metallo-Balance Test analyzes the concentration balance of 17 trace elements in the blood, providing an objective method for evaluating the risks associated with cancer and MCI. This biotechnology is aimed at promoting early diabetes detection and health management strategies in the local community.

Access to Care

The partnership with Sugamo Clinic ensures that residents in the Toshima area can access this groundbreaking test reliably. The continuous availability of the Metallo-Balance Test allows the community to keep a closer eye on their health and engage in preventive care.

Renatech is committed to raising awareness about personal health and providing the community with options for preventive measures, encouraging individuals to take a proactive approach towards health management and lifestyle changes. The significant potential of this test lies in its ability to not only detect illness but also facilitate discussions about lifestyle choices and health trajectories among individuals.

What is the Metallo-Balance Test?

The Metallo-Balance Test is a screening method that objectively evaluates an individual’s risk for cancer and MCI by analyzing the concentration of trace metals in the blood. Here are some highlights of the test:

Simple and Safe Procedure

• - Minimal Blood Requirement: Only a small quantity of 6mL is needed for the test. The procedure is conducted in a controlled environment, ensuring patient safety and comfort.
• - Quick Turnaround: The blood sample collection takes approximately 15 minutes, allowing for a brief and low-impact experience for the patient.

Comprehensive Cancer Risk Evaluation

• - Multi-site Cancer Assessment: A single blood sample allows for the assessment of cancer risks across various sites. For men, this includes lung, gastric, liver, pancreas, colorectal, and prostate cancers, while women are screened for the same plus breast, cervical, and ovarian cancers, providing a scoring system from A to D based on risk levels.

Inclusive Cognitive Risk Evaluation

• - Broad Evaluative Scope: The test comprehensively assesses the risk for several types of cognitive impairment, including Alzheimer’s disease, vascular dementia, and Lewy body dementia.

Proven Research Backing

The Metallo-Balance Test is supported by extensive research collaborations with institutions such as the Kanagawa Cancer Center and Chiba Cancer Center, and has received grant funding from Japan's Ministry of Economy, Trade and Industry. It has been patented internationally across nine countries and boasts a total of over 100,000 participants since its inception from April 2019 to March 2026.

Booking Your Test

To undergo the Metallo-Balance Test, it is essential to book your appointment approximately three weeks in advance, as the procedure requires pre-approval via mailed documentation. To make an appointment, patients can either call or visit the designated website.

Important Pre-Test Guidelines

• - Fast Requirements: Patients must refrain from eating or drinking alcohol from 9 PM the day before the test. Hydration is encouraged prior to the blood draw.
• - Medication Instructions: Routine prescription medications can be taken, but over-the-counter medications and supplements should be avoided the day before.

Costs and Patient Eligibility

The testing is available as self-funded medical care, with cancer risk assessment costing ¥19,800 and cognitive risk assessment also priced at ¥19,800. A bundled option is available for both tests at a discounted rate.

The test is available for Japanese nationals aged between 20-80 for cancer assessment and 50-80 for cognitive assessment. Therefore, while patients outside these age brackets or with foreign nationality may be eligible, their results should be considered as reference points.

Conclusion

Renatech is at the forefront of innovation in healthcare, striving to enhance disease risk evaluations through the Metallo-Balance Test. With established protocols, research, and community-focused services like those provided at Sugamo Clinic, they are committed to improving patient health and paving the way for preventive care in Japan.